192 related articles for article (PubMed ID: 12848973)
1. Autoantibodies to factor VIII with catalytic activity.
Bayry J; Lacroix-Desmazes S; Pashov A; Stahl D; Hoebeke J; Kazatchkine MD; Kaveri SV
Autoimmun Rev; 2003 Jan; 2(1):30-5. PubMed ID: 12848973
[TBL] [Abstract][Full Text] [Related]
2. Factor VIII inhibitor with catalytic activity towards factor VIII.
Lacroix-Desmazes S; Sooryanarayana ; Moreau A; Kazatchkine MD; Kaveri SV
Haematologica; 2000 Oct; 85(10 Suppl):89-92. PubMed ID: 11187883
[TBL] [Abstract][Full Text] [Related]
3. Catalytic activity of antibodies against factor VIII in patients with hemophilia A.
Lacroix-Desmazes S; Moreau A; Sooryanarayana ; Bonnemain C; Stieltjes N; Pashov A; Sultan Y; Hoebeke J; Kazatchkine MD; Kaveri SV
Nat Med; 1999 Sep; 5(9):1044-7. PubMed ID: 10470082
[TBL] [Abstract][Full Text] [Related]
4. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia.
Wootla B; Dasgupta S; Dimitrov JD; Bayry J; Lévesque H; Borg JY; Borel-Derlon A; Rao DN; Friboulet A; Kaveri SV; Lacroix-Desmazes S
J Immunol; 2008 Jun; 180(11):7714-20. PubMed ID: 18490775
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
[TBL] [Abstract][Full Text] [Related]
6. Catalytic antibodies to factor VIII in haemophilia A.
Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S31-4. PubMed ID: 14567533
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of proteolytic antibodies against factor VIII in hemophilia A.
Lacroix-Desmazes S; Bayry J; Misra N; Horn MP; Villard S; Pashov A; Stieltjes N; d'Oiron R; Saint-Remy JM; Hoebeke J; Kazatchkine MD; Reinbolt J; Mohanty D; Kaveri SV
N Engl J Med; 2002 Feb; 346(9):662-7. PubMed ID: 11870243
[TBL] [Abstract][Full Text] [Related]
8. Antibodies with hydrolytic activity towards factor VIII in patients with hemophilia A.
Lacroix-Desmazes S; Misra N; Bayry J; Villard S; Kazatchkine MD; Kaveri SV
J Immunol Methods; 2002 Nov; 269(1-2):251-6. PubMed ID: 12379365
[TBL] [Abstract][Full Text] [Related]
9. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII.
Lacroix-Desmazes S; Wootla B; Dasgupta S; Delignat S; Bayry J; Reinbolt J; Hoebeke J; Saenko E; Kazatchkine MD; Friboulet A; Christophe O; Nagaraja V; Kaveri SV
J Immunol; 2006 Jul; 177(2):1355-63. PubMed ID: 16818797
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives.
Ananyeva NM; Lacroix-Desmazes S; Hauser CA; Shima M; Ovanesov MV; Khrenov AV; Saenko EL
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):109-24. PubMed ID: 15090997
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
[TBL] [Abstract][Full Text] [Related]
12. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.
Towfighi F; Gharagozlou S; Sharifian RA; Kazemnejad A; Esmailzadeh K; Managhchi MR; Shokri F
Acta Haematol; 2005; 114(2):84-90. PubMed ID: 16103630
[TBL] [Abstract][Full Text] [Related]
13. Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors.
Grosbois SS; Brionne MF; de Longcamp AL; Gautier P; V Kaveri S; Borel-Derlon A; Repessé Y
Haemophilia; 2013 Mar; 19(2):322-9. PubMed ID: 23216758
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG.
Moreau A; Lacroix-Desmazes S; Stieltjes N; Saenko E; Kaveri SV; D'Oiron R; Sultan Y; Scandella D; Kazatchkine MD
Blood; 2000 Jun; 95(11):3435-41. PubMed ID: 10828026
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.
Boylan B; Rice AS; Dunn AL; Tarantino MD; Brettler DB; Barrett JC; Miller CH; ;
J Thromb Haemost; 2015 Jan; 13(1):47-53. PubMed ID: 25354263
[TBL] [Abstract][Full Text] [Related]
16. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL
Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754
[TBL] [Abstract][Full Text] [Related]
17. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
[TBL] [Abstract][Full Text] [Related]
18. Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A.
Madoiwa S; Yamauchi T; Kobayashi E; Hakamata Y; Dokai M; Makino N; Kashiwakura Y; Ishiwata A; Ohmori T; Mimuro J; Sakata Y
J Thromb Haemost; 2009 May; 7(5):811-24. PubMed ID: 19220731
[TBL] [Abstract][Full Text] [Related]
19. Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G.
Wootla B; Dasgupta S; Mallet V; Kazatchkine MD; Nagaraja V; Friboulet A; Kaveri SV; Lacroix-Desmazes S
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):229-34. PubMed ID: 16651863
[TBL] [Abstract][Full Text] [Related]
20. B-cell and T-cell epitopes in anti-factor VIII immune responses.
Pratt KP; Thompson AR
Clin Rev Allergy Immunol; 2009 Oct; 37(2):80-95. PubMed ID: 19184559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
